Regeneron Pharmaceuticals announced positive two-year results from the pivotal PHOTON trial investigating aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema. The results were presented at the American Society of Retina Specialists annual meeting. 89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements.